EORTC has successfully conducted clinical research in ovarian, cervical, uterine and vulvar cancer for decades. Many of these trials were unique and changed clinical practice. Today, the Group is focused on molecular approaches to patient management. Their aim is to discover clinically-useful predictive factors to identify subgroups of patients based on genomic patterns and activated pathways, and tailor clinical trials to them. The Group also stimulates clinical trials in rare cancers and underserved populations within the gynecological field.


  • Radiation Oncology Group

    EORTC 22787 – Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma?

    EORTC found that para-aortic irradiation did not provide any benefit to high-risk patients with cervical cancer. It also found that extended field irradiation improved local control but increased digestive complications.

  • Gynecological Group

    EORTC 55865 – Phase III study for the treatment of ovarian cancer FIGO stages IIB and C, III and IV.

    EORTC found that in patients with advanced epithelial ovarian cancer, debulking surgery after chemotherapy, lengthened progression free and overall survival, and reduced risk of death by one third in these patients.


  • Gynecological Group

    EORTC 55904 – Phase III study to evaluate platinum based chemotherapy as an adjuvant to surgery in early ovarian cancer patients.

    EORTC study found that in patients diagnosed with early-stage ovarian cancer with non-optimal surgical staging, additional chemotherapy improves recurrence-free survival.


  • Gynecological Group / QoL

    EORTC 55971 – Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma.

    EORTC found that in patients with stage IIIC or IV epithelial ovarian cancer, timing of surgery (before or after chemotherapy) did not affect survival or health-related quality of life (HRQOL) in these patients. This finding helps enable clinicians to provide evidence-based information to their patient to support decision making.


  • Gynecological Group

    EORTC 44041 – A randomized, multicenter, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

    This EORTC study showed that in patients with stage I or II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer, the addition of the chemotherapy drug erlotinib (EGFR), did not improve progress free or overall survival. However, this study yielded valuable information on the mechanisms of EGFR and related pathways with targeted therapy in ovarian cancer patients.


  • Gynecological Group

    EORTC 55994 – Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.

    EORTC compared two treatment regimens in patients with cervical cancer (FIGO Ib2, IIa >4 cm or IIb cervical cancer) and found that there were no differences in survival between first-line chemotherapy followed by surgery (NACTS), versus simultaneous radiotherapy and chemotherapy (CCRT).


  • Feb-88
  • Mar-95
  • Jan-03
  • Sep-10
  • Feb-14
  • May-19


Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up